Bio Pharma Dive
JUNE 20, 2024
Interim study data suggest the Danish drugmaker can remain in the race to develop new kinds of weight loss drugs as doctors seek alternatives to the now dominant GLP-1s.
Pharmaceutical Technology
JUNE 25, 2024
Merck’s decision follows the independent committee's analysis that the trial is unlikely to meet its primary endpoints.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
JUNE 26, 2024
The failure of a Phase 3 trial led the Wegovy maker to take an accounting charge that will hit its operating profit growth this year.
Bio Pharma Dive
APRIL 16, 2024
Shares of the biotech rose 25% after a large trial found adding its drug Caplyta onto antidepressant therapy significantly helped people with major depression.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials.
Bio Pharma Dive
MARCH 29, 2024
Confirmatory results for Krazati, which Bristol Myers acquired via its buyout of Mirati, could help the drug win full approval while Amgen has been set back.
Pharmaceutical Technology
JULY 2, 2024
The company scrapped the envafolimab trial, after an independent review found the study was unlikely to meet its primary endpoint.
Advertisement
The sourcing of commercial drugs for use in clinical trials either as a comparator, rescue or co-medication can be a complex process. Watch this video to learn more about what to look for when selecting a commercial drug sourcing specialist, as well as Catalent’s approach to this process.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management.
Expert insights. Personalized for you.
265 
Let's personalize your content